Nanostructured nanoparticles of self-assembled lipid pro-drugs as a route to improved chemotherapeutic agents.

We demonstrate that oral delivery of self-assembled nanostructured nanoparticles consisting of 5-fluorouracil (5-FU) lipid prodrugs results in a highly effective, target-activated, chemotherapeutic agent, and offers significantly enhanced efficacy over a commercially available alternative that does not self-assemble. The lipid prodrug nanoparticles have been found to significantly slow the growth of a highly aggressive mouse 4T1 breast tumour, and essentially halt the growth of a human MDA-MB-231 breast tumour in mouse xenografts. Systemic toxicity is avoided as prodrug activation requires a three-step, enzymatic conversion to 5-FU, with the third step occurring preferentially at the tumour site. Additionally, differences in the lipid prodrug chemical structure and internal nanostructure of the nanoparticle dictate the enzymatic conversion rate and can be used to control sustained release profiles. Thus, we have developed novel oral nanomedicines that combine sustained release properties with target-selective activation.

[1]  C. Drummond,et al.  High throughput preparation and characterisation of amphiphilic nanostructured nanoparticulate drug delivery vehicles. , 2010, International journal of pharmaceutics.

[2]  C. Drummond,et al.  Ordered nanostructured amphiphile self-assembly materials from endogenous nonionic unsaturated monoethanolamide lipids in water. , 2010, Langmuir : the ACS journal of surfaces and colloids.

[3]  C. Drummond,et al.  Endogenous nonionic saturated monoethanolamide lipids: solid state, lyotropic liquid crystalline, and solid lipid nanoparticle dispersion behavior. , 2010, The journal of physical chemistry. B.

[4]  C. Drummond,et al.  Soft ordered mesoporous materials from nonionic isoprenoid-type monoethanolamide amphiphiles self-assembled in water , 2009 .

[5]  C. Drummond,et al.  Observing self-assembled lipid nanoparticles building order and complexity through low-energy transformation processes. , 2009, ACS nano.

[6]  P. Couvreur,et al.  Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor. , 2009, Molecular pharmaceutics.

[7]  A. Paci,et al.  Squalenoylation Favorably Modifies the in Vivo Pharmacokinetics and Biodistribution of Gemcitabine in Mice , 2008, Drug Metabolism and Disposition.

[8]  Tycho Heimbach,et al.  Prodrugs: design and clinical applications , 2008, Nature Reviews Drug Discovery.

[9]  F. Kratz,et al.  Prodrug Strategies in Anticancer Chemotherapy , 2008, ChemMedChem.

[10]  B. Boyd,et al.  A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats. , 2007, International journal of pharmaceutics.

[11]  C. Drummond,et al.  Ordered 2-D and 3-D nanostructured amphiphile self-assembly materials stable in excess solvent. , 2006, Physical chemistry chemical physics : PCCP.

[12]  David Cookson,et al.  Strategies for data collection and calibration with a pinhole-geometry SAXS instrument on a synchrotron beamline. , 2006, Journal of synchrotron radiation.

[13]  Oscar Ces,et al.  Pressure-jump X-ray studies of liquid crystal transitions in lipids , 2006, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[14]  M. Michel,et al.  Monoglyceride self-assembly structures as delivery vehicles , 2006 .

[15]  P. Spicer.  Progress in liquid crystalline dispersions: Cubosomes , 2005 .

[16]  A. McDowall,et al.  Submicron Dispersions of Hexosomes Based on Novel Glycerate Surfactants , 2005 .

[17]  J. Mckendrick,et al.  Capecitabine: effective oral fluoropyrimidine chemotherapy , 2005, Expert opinion on pharmacotherapy.

[18]  S. Tokudome,et al.  IDENTIFICATION OF THE CYTOSOLIC CARBOXYLESTERASE CATALYZING THE 5′-DEOXY-5-FLUOROCYTIDINE FORMATION FROM CAPECITABINE IN HUMAN LIVER , 2004, Drug Metabolism and Disposition.

[19]  H. Ishitsuka,et al.  Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine. , 2003, Bioorganic & medicinal chemistry letters.

[20]  I. Kellaway,et al.  Peptide Washout and Permeability from Glyceryl Monooleate Buccal Delivery Systems , 2002, Drug development and industrial pharmacy.

[21]  F. Miller,et al.  Nontransgenic models of breast cancer. , 2000, Breast cancer research : BCR.

[22]  I. Kellaway,et al.  In vitro peptide release from liquid crystalline buccal delivery systems. , 2000, International journal of pharmaceutics.

[23]  H. Ishitsuka,et al.  [Discovery and development of novel anticancer drug capecitabine]. , 1999, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[24]  Calum J. Drummond,et al.  Surfactant self-assembly objects as novel drug delivery vehicles , 1999 .

[25]  J. Fritz,et al.  Carbamate chiral surfactants for capillary electrophoresis , 1999 .

[26]  H. Ishitsuka,et al.  Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. , 1998, European journal of cancer.

[27]  H. Ishitsuka,et al.  Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. , 1998, Biochemical pharmacology.

[28]  P. Mullen,et al.  Effect of matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines , 1996 .

[29]  R. Hamelin,et al.  Steroid hormone receptors and tumorigenicity of sublines from breast tumor metastatic MDA-MB 231 cell line. , 1990, Anticancer research.

[30]  Brian J. Petteys,et al.  Synthesis of Stereoisomerically Pure Monoether Lipids , 1999 .

[31]  K. Larsson.  COLLOIDAL DISPERSIONS OF ORDERED LIPID-WATER PHASES , 1999 .